Workflow
Vicarious Surgical (RBOT) - 2024 Q4 - Annual Results

Financial Performance - Vicarious Surgical achieved a cash burn of 49.1millionforthefullyear2024,inlinewithguidanceofapproximately49.1 million for the full year 2024, in line with guidance of approximately 50 million[7]. - Adjusted net loss for Q4 2024 was 14.4million,or14.4 million, or 2.43 per share, compared to an adjusted net loss of 14.6million,or14.6 million, or 2.50 per share, in Q4 2023[8]. - Net loss for the three months ended December 31, 2024, was 13,926thousand,comparedtoalossof13,926 thousand, compared to a loss of 13,111 thousand in the same period of 2023[23]. - Adjusted net loss for the twelve months ended December 31, 2024, was 63,266thousand,downfrom63,266 thousand, down from 76,262 thousand in 2023, indicating an improvement of approximately 16.9%[23]. - Adjusted EPS for the three months ended December 31, 2024, was (2.43),slightlybetterthan(2.43), slightly better than (2.50) in 2023[23]. Expenses - Operating expenses for Q4 2024 were 15.0million,adecreaseof315.0 million, a decrease of 3% compared to 15.5 million in Q4 2023[5]. - R&D expenses for the full year 2024 were 40.2million,downfrom40.2 million, down from 47.6 million in 2023[6]. - General and administrative expenses for the full year 2024 were 21.9million,comparedto21.9 million, compared to 26.9 million in 2023[6]. - Sales and marketing expenses for the full year 2024 were 4.5million,downfrom4.5 million, down from 6.2 million in 2023[6]. Assets and Liabilities - Total assets decreased from 119,864thousandin2023to119,864 thousand in 2023 to 67,719 thousand in 2024, a decline of approximately 43.5%[20]. - Current assets fell from 100,953thousandin2023to100,953 thousand in 2023 to 51,698 thousand in 2024, representing a decrease of about 48.9%[20]. - Total liabilities decreased from 21,895thousandin2023to21,895 thousand in 2023 to 21,021 thousand in 2024, a reduction of about 4%[20]. - The company reported a total current liabilities increase from 7,280thousandin2023to7,280 thousand in 2023 to 7,667 thousand in 2024, an increase of approximately 5.3%[20]. - Stockholders' equity dropped significantly from 97,969thousandin2023to97,969 thousand in 2023 to 46,698 thousand in 2024, a decline of approximately 52.4%[20]. Strategic Developments - The company completed the integration of its Version 1.0 system and is preparing for its first clinical patients in 2025[2]. - The company has expanded strategic partnerships with LSU Health New Orleans, Temple Health, and University of Illinois Health[5]. - Vicarious Surgical appointed Sarah Romano as Chief Financial Officer, effective April 1, 2025[5]. Shareholder Information - Weighted average shares outstanding increased from 4,866,880 in 2023 to 5,885,589 in 2024, reflecting a rise of about 20.9%[23]. - The change in fair value of warrant liabilities for the twelve months ended December 31, 2024, was 43thousand,comparedto43 thousand, compared to 5,191 thousand in 2023[23].